JBC STAFF FISCAL ANALYSIS HOUSE APPROPRIATIONS COMMITTEE

CONCERNING THE ENFORCEMENT OF REQUIREMENTS IMPOSED ON PHARMACY BENEFIT MANAGERS.

Prime Sponsors: Reps. Jodeh and Ortiz JBC Analyst: Matthew Valeta

Senator Will Phone: 303-866-5434

Date Prepared: March 27, 2023

Appropriation Items of Note

Appropriation Required, Amendment in Packet

TABOR Impact

Fiscal Impact of Bill as Amended to Date

The most recent Legislative Council Staff Revised Fiscal Note (attached) reflects the fiscal impact of the bill as of 03/21/23.

XXX	No Change: Attached LCS Fiscal Note accurately reflects the fiscal impact of the bill
	Update: Fiscal impact has changed due to new information or technical issues
	Update: Fiscal impact has changed due to <i>amendment adopted</i> after LCS Fiscal Note was prepared
	Non-Concurrence: JBC Staff and Legislative Council Staff disagree about the fiscal impact of the bill

Amendments in This Packet for Consideration by Appropriations Committee

Amendment	Description
J.001	Staff-prepared appropriation amendment

Current Appropriations Clause in Bill

The bill requires but does not contain an appropriation clause.

Description of Amendments in This Packet

J.001 Staff has prepared amendment **J.001** (attached) to add a provision appropriating a total of \$206,647 cash funds to the Department of Regulatory Agencies for FY 2023-24 from the Division of Insurance Cash Fund. This provision also states that the appropriation is based on the assumption that the Department will require an additional 2.5 FTE.

JBC Staff Fiscal Analysis 1

Points to Consider

TABOR/ Excess State Revenues Impact

This bill is estimated to increase cash fund revenues by \$270,600 in FY 2023-24 and by \$270,600 in FY 2024-25, which will reduce the available General Fund in each fiscal year by equal amounts. This bill increases the TABOR refund made out of the General Fund by \$270,600 for FY 2023-24, reducing the \$30.0 million General Fund set aside for FY 2023-24 by the same amount.